CDEK
← All drugs Report issue

house dust mite allergen

Allergenapproved

Approved

Mar 13, 1924

House dust mites are various species of acariform mites belonging to the family Pyroglyphidae that are found in association with dust in dwellings. They are known for causing allergies. — Wikipedia

Clinical trial activity

93 trials · 112 clinical orgs · 4 marketing orgs

Phase 1
17
Phase 2
43
Phase 3
26
Phase 4
14

Earliest trial started Sep 1, 2002 (NCT00263549)

Timeline

1920s

  1. Mar 13, 1924

    Jubilant Innovation Ltd. — Earliest FDA Approval

  2. Mar 13, 1924

    Jubilant Innovation Ltd. — NDA Secondary Org

  3. Mar 13, 1924

    Jubilant Innovation Ltd. — NDA Organization

1930s

  1. Jul 11, 1930

    ALK-Abello, S.A. — NDA Secondary Org

1950s

  1. Sep 15, 1958

    Greer Laboratories — NDA Secondary Org

1970s

  1. Mar 12, 1974

    Allermed Laboratories — NDA Secondary Org

2000s

  1. Jan 1, 2004

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedMar 13, 1924

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ae-mite, dermatophagoides pteronyssinus
  • depigoid dermatophagoides pteronyssinus
  • dermatofagoides farinae allergen
  • dermatofagoides pteronyssinus allergen
  • dermatophagoides allergen
  • dermatophagoides farinae allergen
  • dermatophagoides pteronyssinus
  • dermatophagoides pteronyssinus
  • dermatophagoides pteronyssinus allergen
  • dermatophagoides pteronyssinus whole
  • d. pteronyssinus allergens
  • dust mite allergen
  • dust mite extract
  • european house dust mite
  • european house dust mite extract
  • helisen
  • house dust mit allergen
  • house dust mite allergen
  • house dust mite allergen extract placebo
  • house dust mite extract, dermatophagoides pteronyssinus
  • house dust mites allergen extract
  • insects (whole body), mite dermatophagoides farinae
  • insects (whole body), mite dermatophagoides pteronyssinus
  • insects (whole body), mite dermatophagoides pteronyssinus
  • mite allergen extract
  • mite d.p.
  • mite d.p. (dermatophagoides pteronyssinus) standardized
  • mitizax
  • mk-8237
  • mm09 mannosylated
  • pangramin plus d. pteronyssinus
  • purethal mites
  • staloral
  • sublivac fix mite

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07060885Phase 3Sep 30, 2025ALK-Abello, S.A.
NCT07013123Phase 3Jul 15, 2025ALK-Abello, S.A., AstraZeneca, University of Montpellier, University of Nimes
NCT06778213Phase 4Nov 2, 2024Allergopharma GmbH & Co. KG, Wroclaw Medical University
NCT06920771Phase 3Sep 9, 2024Ergomed, HAL Allergy
NCT05113394Phase 2Feb 1, 2024Emory University, George Washington University, Harvard University, Imperial College London, Moorgreen Hospital, Southampton, University of Cincinnati, University of North Carolina at Chapel Hill
NCT05668390Phase 3Oct 1, 2023Philipps University of Marburg, Stallergenes
NCT05641272Phase 2/Phase 3 (Phase 3)Apr 1, 2023Inmunotek S.L., LAT Research, Xolomon Tree S.L.
NCT06509243N/AFeb 10, 2023Silesian University of Medicine
NCT05400811Phase 3Dec 31, 2022BioClever 2005 S.L., Clinica Universidad de Navarra, Inmunotek S.L., University of Navarra
NCT05570383Phase 2/Phase 3 (Phase 3)Dec 1, 2022GMP BIO Co., LTD., Guizhou Medical University
NCT05245175N/AFeb 22, 2022Fraunhofer, University of California, Irvine
NCT05525650Phase 1Jan 20, 2022RAPHAS
NCT05395689Phase 3Jan 17, 2022Probelte Pharma S.L.U.
NCT05119751Phase 4Oct 25, 2021ALK-Abello, S.A., Clinique Spécialisée en Allergies de la Capitale
NCT05019209N/ASep 10, 2021Fraunhofer, Gottfried Wilhelm Leibniz Universität Hannover
NCT04874714Phase 3Apr 30, 2021BioClever 2005 S.L., Clinica Universidad de Navarra, Inmunotek S.L.
NCT04542902N/AOct 1, 2020Lithuanian University of Health Sciences
NCT04435990Phase 3Sep 30, 2020Alergocantabria, Santander, Alergocan, Tenerife, Centro Médico Puerto, Jerez, Clínica Corachan, Barcelona, Clínica IMED, Clinica Privada, Málaga., Clinica Quirón Salud, Córdoba, Clínica TECMA, Alzira, Clínica Virgen del Rosario, Algeciras, Hospital POLUSA, Lugo, Inmunotek S.L., Quirón Málaga, Quirón Palma de Mallorca, Sanatorio Nosa Sra. Dos Ollos Grandes, Lugo, University Hospital Quirón Dexeus, Barcelona, University of Barcelona
NCT04100902Phase 4Dec 1, 2019ALK-Abello, S.A., Lund University, University of Copenhagen
NCT04035109Phase 1/Phase 2 (Phase 2)Oct 31, 2019National Heart, Lung, and Blood Institute (NHLBI), University of North Carolina at Chapel Hill
Showing 20 of 93 trials
Page 1 / 5

Organizations

Research & Development (112)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
ALK-Abello, S.A.For profit141042006
StallergenesFor profit8832007
Inmunotek S.L.For profit6632016
University of North Carolina at Chapel HillAcademic/Hospital6522007
National Heart, Lung, and Blood Institute (NHLBI)Government5032007
Allergopharma GmbH & Co. KGFor profit4222002
HAL AllergyFor profit4422009
Medical University of LodzAcademic/Hospital4412006
MerckFor profit4432012
Roxall MedizinFor profit4422011
Gachon UniversityAcademic/Hospital3312013
Harvard UniversityAcademic/Hospital3322012
Silesian University of MedicineAcademic/Hospital3332008
BioClever 2005 S.L.For profit2012021
Clinica Universidad de NavarraAcademic/Hospital2012021
Cytos Biotechnology AGFor profit2212006
ErgomedFor profit2012011
FraunhoferFor profit2212021
Gottfried Wilhelm Leibniz Universität HannoverAcademic/Hospital2022006
Hospital Virgen del CaminoAcademic/Hospital2022006
112 organizations
Page 1 / 6

Marketing (5)

OrganizationOrg typeRelationshipDate
ALK-Abello, S.A.For profitNDA2Jul 11, 1930
Allermed LaboratoriesFor profitNDA2Mar 12, 1974
Greer LaboratoriesFor profitNDA2Sep 15, 1958
Jubilant Innovation Ltd.For profitNDA2Mar 13, 1924
Jubilant Innovation Ltd.For profitNDAMar 13, 1924